SR
BIIB icon

Swiss Re’s Biogen BIIB Stock Holding History

Swiss Re’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5K Hold
90
– – 0.1% 155
2025
Q4 		$15.8K Buy
+90
New +$14.7K ﹤0.01% 163

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Swiss Re's BIIB Position: Q1 2026 in Review

Swiss Re held its Biogen (BIIB) position steady in Q1 2026 at 90 shares worth $16.5K. The position accounts for 0.1% of the portfolio, ranked #155.

Swiss Re first reported a position in BIIB in Q4 2025 and has held it in 2 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Swiss Re held 90 shares of Biogen worth $16.5K as of Q1 2026.
  • Swiss Re left its Biogen share count unchanged in Q1 2026.
  • Biogen made up 0.1% of Swiss Re's portfolio in Q1 2026, its #155 holding.
  • Swiss Re first reported a position in Biogen in Q4 2025 and has held it in 2 quarters since.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Swiss Re's 13F filing for Q1 2026, filed 12 May 2026.